Press Release - Company Data

BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors
Posted 2014-07-22 00:11NAI Editing
announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board.

BioDelivery Sciences Announces Completion of Patient Enrollment in its Initial Phase 3 Trial of Clonidine Topical Gel for Painful Diabetic Neuropathy
Posted 2014-06-26 00:07NAI Editing
announced that it has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN).

BioDelivery Sciences Receives FDA Approval for BUNAVAIL™ (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence
Posted 2014-06-08 23:37NAI Editing
received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).

BioDelivery Sciences Announces Randomization of Over 50% of Subjects in its Initial Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy
Posted 2014-05-05 23:34NAI Editing
announced that it has randomized more than half of the planned number of patients required for its ongoing initial Phase 3 study of Clonidine Topical Gel, BDSI's proposed treatment for painful diabeti

BioDelivery Sciences Announces Enrollment of the First Patient in a Phase 3 Clinical Study of Clonidine Topical Gel for Painful Diabetic Neuropathy
Posted 2014-04-02 23:34NAI Editing
announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.

BioDelivery Sciences Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the U.S.
Posted 2014-03-26 23:39NAI Editing
announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed ma

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report
Posted 2014-03-13 23:37NAI Editing
announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the U.S.

BioDelivery Sciences Closes $60 Million Registered Direct Offering
Posted 2014-02-13 00:10NAI Editing
announced that it has closed its previously announced registered direct offering with a select group of institutional investors under which such investors have purchased an aggregate of 7,500,000 shar

BioDelivery Sciences to Raise $60 Million in Registered Direct Offering From Institutional Investors
Posted 2014-02-09 23:56NAI Editing
announced that it has entered into a definitive securities purchase agreement with a select group of institutional investors led by Federated Kaufmann under which such investors have committed to purc

BioDelivery Sciences Provides an Update of Anticipated 2014 Milestones
Posted 2014-01-10 00:00NAI Editing
announced updates to the company's anticipated 2014 milestones for its product portfolio, including the imminent database lock for the Phase 3 clinical study of BEMA Buprenorphine for the treatment of